dehydroepiandrosterone and Dyspareunia studies

Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.

Dyspareunia: Recurrent genital pain occurring during, before, or after SEXUAL INTERCOURSE in either the male or the female.

Research Excerpts

Excerpt	Relevance	Reference
"Intravaginal dehydroepiandrosterone (DHEA) is a locally metabolised estrogen and androgen precursor, licensed in 2018 in the EU for moderate to severe vulvovaginal atrophy in postmenopausal women."	9.51	Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient? ( Bruce, D; Holloway, D; Kearley-Shiers, K, 2022)
"The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)."	9.27	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; BSc, AB; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2018)
"The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)."	9.22	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; Beauregard, A; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2016)
"5 mg) dehydroepiandrosterone (DHEA, prasterone) for 12 weeks has shown clinically and statistically significant effects on moderate to severe (MS) dyspareunia as the most bothersome symptom (MBS), the present study analyzes the effect of a reduced dosing regimen on MBS vaginal dryness."	9.20	Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. ( Archer, DF; Ayotte, N; Balser, J; Bouchard, C; Cooper, TA; Côté, I; Elfassi, É; Grainger, DA; Koltun, W; Labrie, C; Labrie, F; Lavoie, L; Martel, C; Martens, M; Portman, DJ; Waldbaum, AS, 2015)
"To examine the effect of intravaginal dehydroepiandrosterone (DHEA) on pain at sexual activity (dyspareunia) identified as the most bothersome symptom of vaginal atrophy in postmenopausal women at both screening and day 1."	9.15	Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. ( Archer, DF; Ayotte, N; Balser, J; Baron, M; Berger, L; Bouchard, C; Côté, I; Cusan, L; Dubé, R; Fortier, M; Gilbert, L; Girard, G; Gomez, JL; Labrie, C; Labrie, F; Lavoie, L; Martel, C; Moreau, M, 2011)
"To compare treatment efficacy and safety parameters a total of 55 premenopausal women with histologically proven endometriosis (stage II-IV) were randomized to receive the LHRH-analogue depot triptorelin (n = 30) or the steroid danazol (n = 25) for a total of 24 weeks."	9.08	A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. ( Cirkel, U; Ochs, H; Schneider, HP, 1995)
"The effects of intravaginal administration of dehydroepiandrosterone (DHEA) for the management of symptomatic vulvovaginal atrophy are reviewed."	8.91	Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. ( Archer, DF, 2015)
"Intravaginal dehydroepiandrosterone (DHEA) is a locally metabolised estrogen and androgen precursor, licensed in 2018 in the EU for moderate to severe vulvovaginal atrophy in postmenopausal women."	5.51	Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient? ( Bruce, D; Holloway, D; Kearley-Shiers, K, 2022)
"The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)."	5.27	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; BSc, AB; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2018)
" Topical interventions (vaginal gels or creams) were able to alleviate vaginal dryness and dyspareunia, with intravaginal dehydroepiandrosterone (DHEA) (6."	5.22	Efficacy of interventions to manage sexual dysfunction in women with cancer: a systematic review. ( Febrina, F; Marino, JL; Peate, M; Triyoga, IF; White, M, 2022)
"The objective of the study is to evaluate the acceptability of the intravaginal administration of ovules/suppositories of DHEA (dehydroepiandrosterone, prasterone) for the treatment of vulvovaginal atrophy (VVA) in women with moderate to severe dyspareunia who were administered daily for 12 weeks intravaginal 0."	5.22	Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. ( Archer, DF; Balser, J; Beauregard, A; Côté, I; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, E; Vaillancourt, M; Zerhouni, J, 2016)
"The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)."	5.22	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; Beauregard, A; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2016)
"5 mg) dehydroepiandrosterone (DHEA, prasterone) for 12 weeks has shown clinically and statistically significant effects on moderate to severe (MS) dyspareunia as the most bothersome symptom (MBS), the present study analyzes the effect of a reduced dosing regimen on MBS vaginal dryness."	5.20	Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. ( Archer, DF; Ayotte, N; Balser, J; Bouchard, C; Cooper, TA; Côté, I; Elfassi, É; Grainger, DA; Koltun, W; Labrie, C; Labrie, F; Lavoie, L; Martel, C; Martens, M; Portman, DJ; Waldbaum, AS, 2015)
"To compare treatment efficacy and safety parameters a total of 55 premenopausal women with histologically proven endometriosis (stage II-IV) were randomized to receive the LHRH-analogue depot triptorelin (n = 30) or the steroid danazol (n = 25) for a total of 24 weeks."	5.08	A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. ( Cirkel, U; Ochs, H; Schneider, HP, 1995)
" estradiol, dehydroepiandrosterone [DHEA], progesterone) that causes menopause commonly affects a woman's general health and produces bothersome physical changes that may interfere with normal sexual and genitourinary functioning."	5.01	Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. ( Goldstein, SR; Kagan, R; Portman, DJ, 2019)
"The effects of intravaginal administration of dehydroepiandrosterone (DHEA) for the management of symptomatic vulvovaginal atrophy are reviewed."	4.91	Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. ( Archer, DF, 2015)
" The use of estrogen agonists/antagonists and intravaginal dehydroepiandrosterone (DHEA) have both been shown to positively affect vaginal atrophy symptoms without inducing endometrial proliferation."	4.86	Vulvovaginal atrophy: current and future therapies (CME). ( Ibe, C; Simon, JA, 2010)
" More recently, double-blind, placebo-controlled clinical trials have demonstrated that local vaginal dehydroepiandrosterone improves symptoms in postmenopausal women, including moderate to severe dyspareunia."	3.88	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. ( Archer, DF; Bachmann, G; Davis, SR; Goldstein, AT; Goldstein, I; Kellogg-Spadt, S; Kim, NN; Lowenstein, L; Nappi, RE; Pinkerton, JV; Simon, JA; Stuenkel, CA; Traish, AM; Vignozzi, L, 2018)

Research

Studies (30)

Authors

Clinical Trials (17)

Trial Overview

Trial Outcomes

Change From Baseline to Week 12 of Vaginal Color

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (6.67)	18.2507
2000's	0 (0.00)	29.6817
2010's	24 (80.00)	24.3611
2020's	4 (13.33)	2.80

Authors	Studies
Febrina, F	1
Triyoga, IF	1
White, M	1
Marino, JL	1
Peate, M	1
Kearley-Shiers, K	1
Holloway, D	1
Bruce, D	1
Cipriani, S	1
Maseroli, E	1
Ravelli, SA	1
Vignozzi, L	2
Gajarawala, SN	1
Wood, TA	1
Stanton, AP	1
Holton, M	1
Thorne, C	1
Goldstein, AT	2
Shifren, JL	1
Simon, JA	2
Goldstein, I	1
Kim, NN	1
Davis, SR	1
Kellogg-Spadt, S	1
Lowenstein, L	1
Pinkerton, JV	1
Stuenkel, CA	1
Traish, AM	1
Archer, DF	11
Bachmann, G	1
Nappi, RE	1
Labrie, F	10
Koltun, W	6
Vachon, A	3
Young, D	3
Frenette, L	3
Portman, D	3
Montesino, M	5
Côté, I	10
Parent, J	3
Lavoie, L	10
BSc, AB	1
Martel, C	10
Vaillancourt, M	5
Balser, J	10
Moyneur, É	6
Portman, DJ	4
Goldstein, SR	1
Kagan, R	1
Hayes, R	1
Birch, M	1
Heo, YA	1
Archer, D	1
Bouchard, C	5
Fortier, M	2
Cusan, L	4
Gomez, JL	2
Girard, G	3
Baron, M	3
Ayotte, N	4
Moreau, M	2
Dubé, R	2
Labrie, C	5
Gilbert, L	2
Elfassi, É	1
Grainger, DA	1
Cooper, TA	1
Martens, M	1
Waldbaum, AS	2
Gallagher, JC	1
Blouin, F	1
Beauregard, A	5
Scheffers, CS	1
Armstrong, S	1
Cantineau, AE	1
Farquhar, C	1
Jordan, V	1
Derogatis, L	1
Zerhouni, J	1
Gandhi, J	1
Chen, A	1
Dagur, G	1
Suh, Y	1
Smith, N	1
Cali, B	1
Khan, SA	1
Aschenbrenner, DS	1
Basson, R	1
Wierman, ME	1
van Lankveld, J	1
Brotto, L	1
Ibe, C	1
Berger, L	1
Dickson, GM	1
Cirkel, U	1
Ochs, H	1
Schneider, HP	1
Kuckatz, C	1
Eicher, W	1
Klinga, K	1
Mueck, AO	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-blind, Placebo-controlled Trial on the Preventive Effect of Intravaginal Prasterone (DHEA, Intrarosa®) on Recurrent Urinary Tract Infections in Women With Genitourinary Syndrome of Menopause[NCT03854396]	Phase 3	0 participants (Actual)	Interventional	2020-05-31	Withdrawn (stopped due to due to termination of ISR by PI with agreement by grant sponsor)
Open-Label Vulvoscopy Photography Study of Changes in Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Administration of 6.5 Mg Vaginal Prasterone in Menopausal Women With Moderate to Severe Dyspareunia[NCT03568604]	Phase 4	18 participants (Actual)	Interventional	2018-08-07	Completed
Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)[NCT01846442]	Phase 3	218 participants (Actual)	Interventional	2007-06-30	Completed
[NCT01358760]	Phase 3	450 participants (Actual)	Interventional	2011-06-30	Completed
A Review on the Clinical Outcome of Chinese Women With Moderate to Severe Symptoms of Genitourinary Syndrome of Menopause (GSM) Treated With Vaginal Dehydroepiandrosterone (DHEA)[NCT05434351]		4 participants (Actual)	Observational	2022-08-01	Terminated (stopped due to inadequate sample and only few patients were prescribed with vaginal DHEA)
Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study)[NCT03740945]	Phase 3	0 participants (Actual)	Interventional	2018-11-06	Withdrawn (stopped due to Business decision to not perform this study.)
DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA)[NCT01256684]	Phase 3	255 participants (Actual)	Interventional	2010-12-31	Completed
A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy[NCT03782480]	Phase 3	40 participants (Anticipated)	Interventional	2019-03-02	Recruiting
DHEA Against Vaginal Atrophy - Safety Study of 12 Months[NCT01256671]	Phase 3	530 participants (Actual)	Interventional	2010-12-31	Completed
[NCT02013544]	Phase 3	558 participants (Actual)	Interventional	2014-02-28	Completed
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)[NCT03619005]	Phase 3	0 participants (Actual)	Interventional	2018-11-13	Withdrawn (stopped due to Business decision to not continue this study (only few subjects were screened).)
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)[NCT03287232]	Phase 3	653 participants (Actual)	Interventional	2017-10-16	Completed
Compare the Effectiveness and Side Effects of Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause[NCT05483634]		40 participants (Anticipated)	Observational	2022-10-28	Not yet recruiting
Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.[NCT05585476]		98 participants (Anticipated)	Interventional	2022-12-31	Not yet recruiting
Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman: A Randomized Placebo-controlled Trial[NCT05627791]	Phase 2/Phase 3	6 participants (Actual)	Interventional	2022-11-30	Terminated (stopped due to Unable to recuit participant number in time.)
Photobiomodulation Effect on Vulvovaginal Atrophy in Postmenopausal Women: Randomized and Controlled Trial.[NCT04487392]	Phase 2	0 participants (Actual)	Interventional	2020-12-15	Withdrawn (stopped due to The student do not start the study)
Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705]	Phase 4	280 participants (Anticipated)	Interventional	2008-04-30	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 of Vaginal Epithelial Integrity

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	3.0	2.0	-1.0
0.50% DHEA	3.1	1.8	-1.3
1.00% DHEA	3.1	1.6	-1.5
Placebo	3.1	2.7	-0.5

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 of Vaginal Epithelial Surface Thickness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	2.7	1.7	-1.0
0.50% DHEA	2.8	1.5	-1.3
1.00% DHEA	2.7	1.4	-1.3
Placebo	2.8	2.4	-0.4

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial surface thickness(one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 of Vaginal Secretions

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	2.9	1.9	-1.0
0.50% DHEA	3.1	1.8	-1.3
1.00% DHEA	3.0	1.6	-1.4
Placebo	3.0	2.6	-0.4

To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Co-primary Endpoint: Change From Baseline to Week 12 of Self-assessment of the Most Bothersome Symptom Dyspareunia

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	3.1	1.9	-1.2
0.50% DHEA	3.2	1.8	-1.4
1.00% DHEA	3.0	1.5	-1.4
Placebo	3.1	2.7	-0.4

The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Parabasal Cells)

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	2.8	1.4	-1.3
0.50% DHEA	2.7	1.1	-1.6
1.00% DHEA	2.6	1.2	-1.4
Placebo	2.8	2.3	-0.4

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Superficial Cells)

Intervention	percentage of parabasal cells (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	65.5	16.9	-48.6
0.50% DHEA	53.4	11.0	-42.4
1.00% DHEA	61.8	6.90	-54.9
Placebo	46.7	47.8	1.1

The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal pH.

Intervention	percentage of superficial cells (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	0.4	5.7	5.3
0.50% DHEA	0.4	5.2	4.8
1.00% DHEA	0.4	6.5	6.1
Placebo	0.6	0.5	-0.1

A pH strip was applied directly to the lateral wall of the vagina using forceps. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Intervention	pH (Mean)
	Baseline	Week 12	Change from Baseline
0.25% DHEA	6.6	5.5	-1.1
0.50% DHEA	6.6	5.2	-1.5
1.00% DHEA	6.5	5.1	-1.4
Placebo	6.5	6.0	-0.5

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Intervention	percentage of parabasal cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	56.74	39.23	-17.51
0.50% DHEA	59.54	33.02	-26.52
Placebo	60.66	62.22	1.56

Change From Baseline to Week 12 in Severity of Dyspareunia

Intervention	percentage of superficial cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	1.12	3.43	2.31
0.50% DHEA	0.93	3.58	2.66
Placebo	0.97	1.80	0.83

The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.58	1.48	-1.10
0.50% DHEA	2.60	1.54	-1.06
Placebo	2.56	1.78	-0.78

The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.37	1.10	-1.28
0.50% DHEA	2.35	1.13	-1.22
Placebo	2.38	1.27	-1.12

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.60	2.16	-0.45
0.50% DHEA	2.65	2.12	-0.53
Placebo	2.66	2.31	-0.35

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.19	1.74	-0.46
0.50% DHEA	2.19	1.69	-0.50
Placebo	2.32	1.94	-0.38

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.66	2.25	-0.40
0.50% DHEA	2.72	2.16	-0.56
Placebo	2.78	2.40	-0.38

To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Vaginal pH

Intervention	Severity score (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.55	2.07	-0.48
0.50% DHEA	2.55	2.07	-0.48
Placebo	2.71	2.33	-0.38

A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01358760)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Intervention	pH units (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	6.27	5.69	-0.58
0.50% DHEA	6.29	5.67	-0.62
Placebo	6.34	6.06	-0.28

The percentage of parabasal cell was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including the basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Intervention	Percentage of parabasal cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	65.72	28.43	-37.29
0.50% DHEA	65.05	17.65	-47.40
Placebo	68.48	66.86	-1.62

The percentage of superficial cell was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including the basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

Intervention	Percentage of superficial cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	0.68	5.43	4.75
0.50% DHEA	0.68	6.30	5.62
Placebo	0.73	1.64	0.91

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.56	1.54	-1.01
0.50% DHEA	2.63	1.36	-1.27
Placebo	2.58	1.71	-0.87

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.94	2.27	-0.67
0.50% DHEA	2.94	2.05	-0.89
Placebo	2.82	2.56	-0.26

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.57	1.92	-0.65
0.50% DHEA	2.57	1.69	-0.88
Placebo	2.58	2.13	-0.45

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.90	2.32	-0.58
0.50% DHEA	2.89	2.14	-0.75
Placebo	2.91	2.57	-0.34

To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Severity of Vaginal Dryness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.81	2.10	-0.71
0.50% DHEA	2.83	1.95	-0.88
Placebo	2.78	2.36	-0.42

The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12

Change From Baseline to Week 12 in Vaginal pH

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	2.20	0.91	-1.29
0.50% DHEA	2.37	0.92	-1.45
Placebo	2.33	1.32	-1.02

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Dyspareunia

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.25% DHEA	6.48	5.70	-0.77
0.50% DHEA	6.47	5.43	-1.04
Placebo	6.51	6.31	-0.21

The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Irritation/Itching

Intervention	units on a scale (Mean)
	Baseline: Subgroup MS	Week 52: Subgroup MS	Change from Baseline: Subgroup MS	Baseline: Subgroup MBS/MS	Week 52: Subgroup MBS/MS	Change from Baseline: Subgroup MBS/MS
0.50% DHEA	2.53	0.85	-1.68	2.57	0.87	-1.69

The severity of irritation/itching was evaluated by a questionnaire. The severity of irritation/itching recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Vaginal Dryness

Intervention	units on a scale (Mean)
	Baseline: Subgroup MS	Week 52: Subgroup MS	Change from Baseline: Subgroup MS	Baseline: Subgroup MBS/MS	Week 52: Subgroup MBS/MS	Change from Baseline: Subgroup MBS/MS
0.50% DHEA	2.10	0.60	-1.50	2.13	0.74	-1.39

The severity of vaginal dryness was evaluated by a questionnaire. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Parabasal Cells).

Intervention	units on a scale (Mean)
	Baseline: Subgroup MS	Week 52: Subgroup MS	Change from Baseline: Subgroup MS	Baseline: Subgroup MBS/MS	Week 52: Subgroup MBS/MS	Change from Baseline: Subgroup MBS/MS
0.50% DHEA	2.22	0.59	-1.63	2.19	0.67	-1.52

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Superficial Cells).

Intervention	percentage of parabasal cells (Mean)
	Baseline: Subgroup ALL	Week 52: Subgroup ALL	Change from Baseline: Subgroup ALL	Baseline: Subgroup VVA	Week 52: Subgroup VVA	Change from Baseline: Subgroup VVA
0.50% DHEA	55.49	12.81	-42.67	63.95	14.80	-49.14

The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 52 of Vaginal pH.

Intervention	percentage of superficial cells (Mean)
	Baseline: Subgroup ALL	Week 52: Subgroup ALL	Change from Baseline: Subgroup ALL	Baseline: Subgroup VVA	Week 52: Subgroup VVA	Change from Baseline: Subgroup VVA
0.50% DHEA	2.02	9.42	7.41	0.96	8.81	7.85

A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium

Intervention	pH (Mean)
	Baseline: Subgroup ALL	Week 52: Subgroup ALL	Change from Baseline: Subgroup ALL	Baseline: Subgroup VVA	Week 52: Subgroup VVA	Change from Baseline: Subgroup VVA
0.50% DHEA	6.23	5.09	-1.14	6.40	5.13	-1.27

The long-term safety of intravaginal prasterone has been evaluated on different parameters including the endometrium. For this purpose, endometrial biopsies were performed at screening and at the end of the study (52 weeks) or at discontinuation visit for women who were exposed to intravaginal DHEA (prasterone) for at least 12 weeks. At screening, the endometrium had to be atrophic/inactive for women to be enrolled in the study. Only the end-of-study data are presented. (NCT01256671)
Timeframe: Baseline and Week 52 (or discontinuation)

Long-term Safety of Intravaginal Prasterone (DHEA): Serum Steroid Levels

Intervention	Participants (Count of Participants)
	Endometrium: Atrophic/Inactive	Endometrium: No/Insufficient Tissue for Diagnosis
0.50% DHEA	421	36

The long-term safety of intravaginal prasterone has been evaluated on different parameters including the serum levels of DHEA and its metabolites. For this purpose, blood samples were collected at Baseline and different post-Baseline timepoints for the determination of serum steroid levels by a central laboratory using validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods. The serum levels of dehydroepiandrosterone (DHEA), estradiol (E2) and testosterone (TESTO) obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Intervention	pg/mL (Mean)
	DHEA: Baseline	DHEA: Week 52	DHEA: Change from Baseline	E2: Baseline	E2: Week 52	E2: Change from Baseline	TESTO: Baseline	TESTO: Week 52	TESTO: Change from Baseline
0.50% DHEA	2071.61	2997.25	925.65	6.05	4.46	-1.59	161.28	189.44	28.17

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Intervention	Percentage of parabasal cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	54.25	12.74	-41.51
Placebo	51.66	39.68	-11.98

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

Intervention	Percentage of superficial cells (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	1.02	11.22	10.20
Placebo	1.04	2.78	1.75

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.54	1.13	-1.42
Placebo	2.56	1.50	-1.06

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.75	2.03	-0.73
Placebo	2.67	2.34	-0.33

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.45	1.75	-0.69
Placebo	2.43	2.06	-0.37

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.83	2.09	-0.74
Placebo	2.76	2.41	-0.36

Change From Baseline to Week 12 in Severity of Vaginal Dryness

Intervention	units on a scale (Mean)
	Baseline	Week 12	Change from Baseline to Week 12
0.50% Prasterone (DHEA)	2.70	1.97	-0.73
Placebo	2.63	2.24	-0.39

Change From Baseline to Week 12 in Vaginal pH

Article	Year
Efficacy of interventions to manage sexual dysfunction in women with cancer: a systematic review. Menopause (New York, N.Y.), 2022, 05-01, Volume: 29, Issue:5 Topics: Cancer Survivors; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Male; Neoplasms; Randomized C	2022
The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA. Climacteric : the journal of the International Menopause Society, 2023, Volume: 26, Issue:4 Topics: Administration, Intravaginal; Androgens; Atrophy; Dehydroepiandrosterone; Dyspareunia; Estrogens; Fe	2023
An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:4 Topics: Administration, Intravaginal; Androgens; Atrophy; Dehydroepiandrosterone; Dyspareunia; Estrogens; Fe	2020
Genitourinary Syndrome of Menopause. Clinical obstetrics and gynecology, 2018, Volume: 61, Issue:3 Topics: Administration, Intravaginal; Administration, Oral; Atrophy; Dehydroepiandrosterone; Dyspareunia; Es	2018
Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. Climacteric : the journal of the International Menopause Society, 2019, Volume: 22, Issue:1 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Menopaus	2019
Prasterone (Intrarosa) for Dyspareunia. American family physician, 2019, 01-15, Volume: 99, Issue:2 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Dehydroepiandrosterone; Dyspareunia; Female; H	2019
Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. The Journal of steroid biochemistry and molecular biology, 2015, Volume: 145 Topics: Atrophy; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Hydrogen-Ion Concentration; Libido; Ov	2015
Dehydroepiandrosterone for women in the peri- or postmenopausal phase. The Cochrane database of systematic reviews, 2015, Jan-22, Volume: 1 Topics: Acne Vulgaris; Dehydroepiandrosterone; Dyspareunia; Estrogens; Female; Hot Flashes; Humans; Perimeno	2015
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016, Volume: 215, Issue:6 Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human	2016
Vulvovaginal atrophy: current and future therapies (CME). The journal of sexual medicine, 2010, Volume: 7, Issue:3 Topics: Adjuvants, Immunologic; Aged; Atrophy; Dehydroepiandrosterone; Drug Administration Schedule; Drug Th	2010

Article	Year
Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient? Post reproductive health, 2022, Volume: 28, Issue:4 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Menopaus	2022
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2018, Volume: 25, Issue:11 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehyd	2018
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. The journal of sexual medicine, 2014, Volume: 11, Issue:7 Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind	2014
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. The journal of sexual medicine, 2014, Volume: 11, Issue:7 Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind	2014
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. The journal of sexual medicine, 2014, Volume: 11, Issue:7 Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind	2014
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. The journal of sexual medicine, 2014, Volume: 11, Issue:7 Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind	2014
Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:4 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause (New York, N.Y.), 2015, Volume: 22, Issue:9 Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia;	2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 2015, Volume: 81, Issue:1 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 2015, Volume: 81, Issue:1 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 2015, Volume: 81, Issue:1 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 2015, Volume: 81, Issue:1 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Coitu	2015
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Coitu	2015
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Coitu	2015
Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric : the journal of the International Menopause Society, 2015, Volume: 18, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Coitu	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. The journal of sexual medicine, 2015, Volume: 12, Issue:12 Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys	2015
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:3 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Fem	2016
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:3 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Fem	2016
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:3 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Fem	2016
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016, Volume: 32, Issue:3 Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Fem	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:3 Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female	2016
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric : the journal of the International Menopause Society, 2011, Volume: 14, Issue:2 Topics: Administration, Intravaginal; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Double-Blind	2011
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric : the journal of the International Menopause Society, 2011, Volume: 14, Issue:2 Topics: Administration, Intravaginal; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Double-Blind	2011
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric : the journal of the International Menopause Society, 2011, Volume: 14, Issue:2 Topics: Administration, Intravaginal; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Double-Blind	2011
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric : the journal of the International Menopause Society, 2011, Volume: 14, Issue:2 Topics: Administration, Intravaginal; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Double-Blind	2011
A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. European journal of obstetrics, gynecology, and reproductive biology, 1995, Volume: 59, Issue:1 Topics: Adult; Danazol; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Delayed-Action Preparations;	1995
[The effects of hormone replacement therapy on ovarian function in premenopausal women after hysterectomy]. Zentralblatt fur Gynakologie, 1999, Volume: 121, Issue:5 Topics: Adult; Dehydroepiandrosterone; Dyspareunia; Estradiol; Estrogen Replacement Therapy; Female; Follicl	1999

Article	Year
What is the role of dehydroepiandrosterone in gynecologic practice? JAAPA : official journal of the American Academy of Physician Assistants, 2019, Volume: 32, Issue:12 Topics: Administration, Intravaginal; Administration, Oral; Atrophy; Dehydroepiandrosterone; Dyspareunia; Fe	2019
Prasterone (Intrarosa) for dyspareunia. The Medical letter on drugs and therapeutics, 2017, 09-11, Volume: 59, Issue:1529 Topics: Administration, Intravaginal; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Postmenopause; Tr	2017
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause (New York, N.Y.), 2018, Volume: 25, Issue:7 Topics: Administration, Intravaginal; Aged; Androgens; Atrophy; Consensus; Dehydroepiandrosterone; Dyspareun	2018
Prasterone: A Review in Vulvovaginal Atrophy. Drugs & aging, 2019, Volume: 36, Issue:8 Topics: Administration, Intravaginal; Atrophy; Clinical Trials, Phase III as Topic; Dehydroepiandrosterone;	2019
New Drug Treats Painful Sexual Intercourse in Postmenopausal Women. The American journal of nursing, 2017, Volume: 117, Issue:3 Topics: Administration, Intravaginal; Dehydroepiandrosterone; Drug Approval; Dyspareunia; Female; Humans; Po	2017
Summary of the recommendations on sexual dysfunctions in women. The journal of sexual medicine, 2010, Volume: 7, Issue:1 Pt 2 Topics: Adjuvants, Immunologic; Dehydroepiandrosterone; Diagnostic and Statistical Manual of Mental Disorder	2010
Menopause management: how you can do better. The Journal of family practice, 2012, Volume: 61, Issue:3 Topics: Acupuncture Therapy; Adjuvants, Immunologic; Administration, Cutaneous; Administration, Topical; Aff	2012

dehydroepiandrosterone and Dyspareunia

Research Excerpts

Research

Studies (30)

Authors

Clinical Trials (17)

Trial Overview

Trial Outcomes

Change From Baseline to Week 12 of Vaginal Color

Change From Baseline to Week 12 of Vaginal Epithelial Integrity

Change From Baseline to Week 12 of Vaginal Epithelial Surface Thickness

Change From Baseline to Week 12 of Vaginal Secretions

Co-primary Endpoint: Change From Baseline to Week 12 of Self-assessment of the Most Bothersome Symptom Dyspareunia

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Parabasal Cells)

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Superficial Cells)

Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal pH.

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Severity of Dyspareunia

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Change From Baseline to Week 12 in Vaginal pH

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Change From Baseline to Week 12 in Severity of Vaginal Dryness

Change From Baseline to Week 12 in Vaginal pH

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Dyspareunia

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Irritation/Itching

Change From Baseline to Week 52 of Self-assessment of VVA Symptom Vaginal Dryness

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Parabasal Cells).

Change From Baseline to Week 52 of Vaginal Cell Maturation (Percentage of Superficial Cells).

Change From Baseline to Week 52 of Vaginal pH.

Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium

Long-term Safety of Intravaginal Prasterone (DHEA): Serum Steroid Levels

Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear

Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Dyspareunia

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Color

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Integrity

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Epithelial Surface Thickness

Change From Baseline to Week 12 in Severity of Vaginal Atrophy as Evaluated From Vaginal Secretions

Change From Baseline to Week 12 in Severity of Vaginal Dryness

Change From Baseline to Week 12 in Vaginal pH

Reviews

Trials

Other Studies